Abstract:Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2) induced Coronavirus Disease - 19 (COVID-19) cases have been increasing at an alarming rate (7.4 million positive cases as on June 11 2020), causing high mortality (4,17,956 deaths as on June 11 2020) and economic loss (a 3.2% shrink in global economy in 2020) across 212 countries globally. The clinical manifestations of this disease are pneumonia, lung injury, inflammation, and severe acute respiratory syndrome (SARS). Currently, there is no vaccine or effective pharmacological agents available for the prevention/treatment of SARS-CoV2 infections. Moreover, development of a suitable vaccine is a challenging task due to antibody-dependent enhancement (ADE) and Th-2 immunopathology, which aggravates infection with SARS-CoV-2. Furthermore, the emerging SARS-CoV-2 strain exhibits several distinct genomic and structural patterns compared to other coronavirus strains, making the development of a suitable vaccine even more difficult. Therefore, the identification of novel small molecule inhibitors (NSMIs) that can interfere with viral entry or viral propagation is of special interest and is vital in managing already infected cases. SARS-CoV-2 infection is mediated by the binding of viral Spike proteins (S-protein) to human cells through a 2-step process, which involves Angiotensin Converting Enzyme-2 (ACE2) and Transmembrane Serine Protease (TMPRSS)-2. Therefore, the development of novel inhibitors of ACE2/TMPRSS2 is likely to be beneficial in combating SARS-CoV-2 infections. However, the usage of ACE-2 inhibitors to block the SARS-CoV-2 viral entry requires additional studies as there are conflicting findings and severe health complications reported for these inhibitors in patients. Hence, the current interest is shifted toward the development of NSMIs, which includes natural antiviral phytochemicals and Nrf-2 activators to manage a SARS-CoV-2 infection. It is imperative to investigate the efficacy of existing antiviral phytochemicals and Nrf-2 activators to mitigate the SARS-CoV-2-mediated oxidative stress. Therefore, in this review, we have reviewed structural features of SARS-CoV-2 with special emphasis on key molecular targets and their known modulators that can be considered for the development of NSMIs.

Swertiamarin and sweroside are potential inhibitors of COVID-19 based on the silico analysis

Computational View Toward the Inhibition of SARS-CoV-2 Spike Glycoprotein and the 3CL Protease.

A Search for Medications to Treat COVID-19 Via in Silico Molecular Docking Models of the SARS-CoV-2 Spike Glycoprotein and 3CL Protease

The exploration of phytocompounds theoretically combats SARS-CoV-2 pandemic against virus entry, viral replication and immune evasion

Strategies for Targeting SARS CoV-2: Small Molecule Inhibitors—The Current Status

Discovery of Polyphenolic Natural Products as SARS-CoV-2 Mpro Inhibitors for COVID-19

Systematic investigation of selected bio-molecules, potentially effective in inhibiting SARS-CoV-2/COVID-19 via in-silico analysis

An Integrated Method for Optimized Identification of Effective Natural Inhibitors Against SARS-CoV-2 3Clpro

Target-Based in Silico Screening for Phytoactive Compounds Targeting SARS-CoV-2

In silico virtual screening, characterization, docking and molecular dynamics studies of crucial SARS-CoV-2 proteins

Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection

Screening for inhibitors against SARS-CoV-2 and its variants

In Silico Evaluation of Iranian Medicinal Plant Phytoconstituents as Inhibitors against Main Protease and the Receptor-Binding Domain of SARS-CoV-2

Identification of potential antiviral compounds against SARS-CoV-2 structural and non structural protein targets: A pharmacoinformatics study of the CAS COVID-19 dataset

Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets

Computational Study of the Therapeutic Potential of Novel Heterocyclic Derivatives against SARS-CoV-2

Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus

Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2

Structure-Based Virtual Screening and Identification of Potential Inhibitors of SARS-CoV-2 S-RBD and ACE2 Interaction

Interactive Mechanism of Potential Inhibitors with Glycosyl for SARS-CoV-2 by Molecular Dynamics Simulation

Identification of Severe Acute Respiratory Syndrome Coronavirus‐2 inhibitors through in silico structure‐based virtual screening and molecular interaction studies